Navigation Links
COX-2 inhibitors significantly reduce risk of cancer

Results from a new, five-year study show that regular use of popular prescription pain relievers may reduce the risk of breast cancer by up to 71 percent and may offer similar benefit in the prevention of prostate, colon and lung cancers.

The study findings were released today at the annual meeting of the American Association for Cancer Research in Washington, D.C.

"We believe this is the first study to show that selective COX-2 inhibitors have significant chemopreventive effects against breast cancer," says Dr. Randall Harris, professor and director of the Center for Molecular Epidemiology and Environmental Health in The Ohio State University College of Medicine and lead author of the study.

The results come from a larger, case-control study of NSAID use and its impact upon the four leading types of cancer in the United States: breast, lung, prostate and colon cancer. NSAIDs are non-steroidal, anti-inflammatory drugs that block the COX-2 enzyme pathway that is often activated in inflammation, cancer, heart disease and other disorders.

Harris and his colleagues studied the use of celecoxib (Celebrex), rofecoxib (Vioxx), regular aspirin, low-dose aspirin, ibuprofen and acetaminophen among 323 women with breast cancer from 1999-2004.

They compared the results with those from a control group of 649 cancer-free women matched for age, race and county of residence.

They discovered that women who used NSAIDs on a regular basis had less breast cancer. Specifically, they found that those who used celecoxib or rofecoxib for at least two years appeared to benefit the most, experiencing a 71 percent reduction in risk of breast cancer. Ibuprofen use over the same period was associated with a 64 percent reduction, while regular aspirin offered a 51 percent reduction in risk of the disease.

On the other hand, acetaminophen, which has a negligible effect upon COX-2 activity, and low-dose aspirin provided no significant ch ange in the risk of breast cancer.

"The COX-2 signaling pathway is important in cancer because when it's activated, it can stimulate many key steps in cancer development, including cell division, inhibition of cell death, angiogenesis (the creation of new blood vessels to nourish growing tumors) and metastasis," says Harris, who is also a member of the OSU Comprehensive Cancer Center.

Harris says his research group is only midway through analyzing data from the other parts of the study, but adds that early results suggest that regular use of selective COX-2 inhibitors appears to provide about the same magnitude of protection from prostate, lung and colon cancer.

"These results suggest strong potential for regular use of these drugs in cancer prevention. Still, we know these drugs may have side effects, so we are not advising people to go out and start taking them until more studies confirm that they are safe and effective," says Harris.

Celebrex is still widely used for pain relief, but Vioxx was pulled off the market in 2004 following reports of heightened risk of heart attacks.

"It's clear that we need to have multiple retrospective and prospective studies to validate these findings," says Harris, who has been studying the impact of COX-2 inhibitors for many years. "Eventually, we may find that regular intake of a low dose of a COX-2 inhibitor may be enough to reset the COX-2 cascade and safely protect people against cancer."


'"/>

Source:Ohio State University Medical Center


Related biology news :

1. New understanding of COX-1 and COX-2 enzymes could revise classification of pain meds
2. Anthrax inhibitors identified by Burnham team
3. Protease inhibitors reach beyond HIV
4. Enzyme inhibitors block replication of SARS virus
5. Sweet water taste paradoxically predicts sweet taste inhibitors
6. High HPV concentrations combined with smoking significantly raise risks of cervical cancer
7. Male circumcision reduces risk of HIV transmission from women to men
8. Deficiency of growth hormone and IGF-1 reduces cancer and kidney disease, but creates other problems
9. Use of PET can reduce, may eliminate more strenuous drug development trials with animals
10. Solutions that reduce death of marine life reeled in by International Smart Gear Competition
11. Physiological effects of reduced gravity on bacteria
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
(Date:3/28/2017)... 2017 The report "Video Surveillance ... Servers, Storage Devices), Software (Video Analytics, VMS), and Service ... Forecast to 2022", published by MarketsandMarkets, the market was ... projected to reach USD 75.64 Billion by 2022, at ... base year considered for the study is 2016 and ...
Breaking Biology News(10 mins):
(Date:5/23/2017)... ... May 23, 2017 , ... ... technology applications, has announced a facility expansion to accommodate its rapid growth. , ... of new workspace and renovation of the existing areas. The expansion includes, a ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge Semantics , the leading provider of ... Bio-IT World Conference and Expo in Boston May 23-25 with a featured speaker ... Anzo Smart Data Lake is also a finalist for the Best of Show award. ...
(Date:5/22/2017)... ... May 22, 2017 , ... ... leaders of the Maryland Biohealth community in developing and issuing recommendations to grow ... U.S. BioHealth Innovation Hub by 2023. , The recommendations are ...
(Date:5/21/2017)... ... 20, 2017 , ... CNSDose is a genetically driven, clinically ... by finding the right antidepressant faster. CNSDose speeds recovery and reduces side ... personalized approach to treatment. , A peer-reviewed and published, 12-week double-blind ...
Breaking Biology Technology: